Bristol-myers Squibb Compnay

Crown Affair, Inc.

Mastercard International Incorporated

Daniel Cohen

Dasa Lipovsek

Paul E Morin

Ray Camphausen

Ranjan Mukherjee

Timothy Patrick Reilly

Rose C Christian

John Krupinski

Maria N Jure-Kunkel

Martin C Wright

David Fabrizio

Jochem Gokemeijer

David J Donnelly

Douglas Dischino

Samuel J Bonacorsi, Jr

Virginie Lafont

Ralph Adam Smith

Alec Wilkins

David K Leung

Sara E Fiebiger

Matthew L Lanford

Jennifer W Vanderwall

Brian J Clubb

Samuel J Bonacorsi

David Donnelly

A contourable product for absorbing moisture includes a main sheet comprising an absorbent material. A number of sides of the main sheet is more than four, with the main sheet defined by a polygonal shape. The main sheet is movable between an unwrapped position and a wrapped position. In the unwrapped position, the main sheet is completely unfolded and substantially flat. In the wrapped position, the main sheet is contoured to secure to and wrap around a human head and extend around head hair of the human head.

Contoured product for absorbing moisture

Nucleic acids encoding modified FGF-21 polypeptides, optionally containing at least one non-codon encoding a naturally-encoded amino acid, and vectors and cells containing are provided. These nucleic acids can be used to express the modified FGF-21 polypeptide encoded thereby. The expressed FGF-21 polypeptides may be used as therapeutics, e.g., in the treatment of diseases associated with fibrosis.

Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof

Provided herein are novelFn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

PD-L1 binding polypeptides for imaging

PET imaging with PD-L1 binding polypeptides

Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides

Provided herein are novel polypeptides comprising fibronectin type III tenth (Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.

Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof

Therapeutic uses of modified FGF-21 polypeptides

A first acquirers receives, via a payment network configured to facilitate transactions between multiple issuers and multiple acquirers, an authorization response flagged with a flag. The flag indicates that clearing of a first transaction, associated with the authorization response, is to be suspended. The first transaction initially has an uncertain amount, and is associated with a first payment account, of a first user, associated with a first issuer. Subsequent determination of a final certain amount for the first transaction is awaited. Upon determination of the final certain amount, the first one of the acquirers proceeds with clearing the first transaction, based on the final certain amount. The steps are repeated for at least a second acquirer and at least a second transaction. The second transaction is associated with a second payment account, of a second user, associated with a second one of the issuers. The steps are carried out by an operator of the payment network, and the flag is understandable to the first and second issuers and the first and second acquirers.

Method and apparatus for processing uncertain transaction amounts in a payment system

Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Growing community of inventors

New York, NY, United States of America

Daniel Cohen